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SQSTM1 (sequestosome 1; also known as p62) encodes a multidomain scaffolding protein involved in various key cellular processes,
including the removal of damaged mitochondria by its function as a selective autophagy receptor. Heterozygous variants in SQSTM1
have been associated with Paget disease of the bone and might contribute to neurodegeneration in amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD). Using exome sequencing, we identified three different biallelic loss-of-function variants in
SQSTM1 in nine affected individuals from four families with a childhood- or adolescence-onset neurodegenerative disorder characterized
by gait abnormalities, ataxia, dysarthria, dystonia, vertical gaze palsy, and cognitive decline. We confirmed absence of the SQSTM1/p62
protein in affected individuals’ fibroblasts and found evidence of a defect in the early response to mitochondrial depolarization and
autophagosome formation. Our findings expand the SQSTM1-associated phenotypic spectrum and lend further support to the concept
of disturbed selective autophagy pathways in neurodegenerative diseases.Neurodegenerative disease causes severe disability or even
early death and many families and affected individuals
remain without a specific molecular diagnosis. The identi-
fication of underlying gene defects in both common and
rare conditions provided fundamental new insights into
pathophysiology and basic cellular processes. Examples
are the discovery of gene defects underlying Parkinson dis-
ease (PD) and amyotrophic lateral sclerosis (ALS). Proteins
encoded by affected genes such as PARKIN (PARK2),
PINK1, OPTN, SQSTM1/p62, and TBK1 offer a new
perspective on the involvement of mitochondria. Specif-
ically, these proteins are thought to be involved in the
maintenance of a functioning pool of mitochondria by
regulating their turnover by selective autophagocytic
processes.1,2 One recent model suggests that after loss of
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signature on mitochondria to induce recruitment of the
primary autophagy adaptors OPTN and NDP52, which
then engage with the autophagy machinery (ULK1,
DFCP1, WIPI1, and LC3).3 Although TBK1-dependent
phosphorylation of OPTN and NDP52 is thought to be
crucial for robust mitophagy, the presence of additional/
alternative autophagy adaptors such as TAX1BP1, NRB1,
and SQSTM1/p62 is dispensable for mitophagy itself.3
In addition to its function in autophagy, the multido-
main scaffold protein SQSTM1/p62 plays a role in diverse
other key cellular pathways; heterozygous SQSTM1 (MIM:
601530) variants have been suggested to contribute to
the pathogenesis of such diverse presentations as Paget
disease of the bone (PDB [MIM: 167250]), ALS, FTD
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Table 1. Genetic and Clinical Findings in Individuals with Biallelic SQSTM1 Loss-of-Function Variants
ID Sex
SQSTM1 Variants Phenotypic Features MRI Findings
cDNA (NM_003900.4),
Protein (NP_003891.1) AaOa AaLEa
Gait





F1:II.1 M c.[2T>A];[2T>A], p.[?];[?] 10 45 þ* þ* þ þ þ þL  ND ND
F1:II.3 F c.[2T>A];[2T>A], p.[?];[?] 12 42 þ* þ þ þ þ þU/L þ*  þ















10 12 þ* þ* þ (þ) þ  þ* þ 
F3:II.1 F c.[286C>T];[286C>T],
p.[Arg96*];[Arg96*]
7 18 þ* þ*  þ*   þ þ 
F4:II.1 F c.[286C>T];[286C>T],
p.[Arg96*];[Arg96*]
8 33 þ þ*  þ þ  þ  
F4:II.4 M c.[286C>T];[286C>T],
p.[Arg96*];[Arg96*]
8 17 þ þ* þ þ þ  þ  
Abbreviations are as follows: AaLE, age at last examination; AaO, age at onset; abn., abnormalities; CA, cerebellar atrophy; MND, motor neuron disorder (L, lower
MND; U/L, upper and lower MND); ND, not done; *, among the presenting symptoms; þ, affected; (þ), mildly affected; , not affected.
aAges in years.rimmed vacuoles.5 Here, we report on the phenotypic
spectrum associated with absence of SQSTM1/p62 as well
as the results of our studies of mitophagy-related pheno-
types in mutant fibroblast cell lines.
We performed exome sequencing on genomic DNA from
affected individuals from four families with a so far etio-
logically unresolved childhood- or adolescence-onset
neurodegenerative syndrome manifesting with gait ab-
normalities and ataxia. Clinical and genetic findings are
summarized in Table 1, pedigrees are shown in Figure 1,
and neuroimaging findings are in Figure 2. A summary of
the phenotypes is provided below, and the detailed indi-
vidual case reports are provided in the Supplemental
Data. Informed consent was obtained from all affected in-
dividuals or their guardians. The study was approved by
the local ethics committees.
Family 1 consists of three affected siblings, one male
(F1:II.1) and two females (F1:II.3, F1:II.6), and three healthy
siblings born to healthy unrelated parents of German
origin.All affected individuals presentedwithgait problems
in their early teen years, progressing to wheelchair depen-
dence at ages 16–32 years. Other presenting symptoms
included urinary incontinence, upper limb ataxia, and
cognitive decline. Last clinical examination at ages 45, 42,
and 33 years, respectively, revealed generalized dystonia,
dysarthria, and a cerebellar syndrome in all three affected
siblings, as well as vertical gaze palsy and a pyramidal syn-
drome in two.None had a history of psychiatric symptoms,736 The American Journal of Human Genetics 99, 735–743, Septembseizures, tremor, or visual impairment. Brain MRI showed
accumulation of iron in basal ganglia in individuals
F1:II.3 and F1:II.6 (Figure 2). A muscle biopsy in F1:II.6
was unremarkable regarding morphology, histochemistry,
ultrastructure, and mitochondrial enzyme analysis.
Family 2 consists of three affected sisters (F2:II.2, F2:II.3,
F2:II.4) and nine reportedly healthy siblings, born to
healthy parents from the United Arab Emirates who were
unaware of consanguinity. All affected siblings had a
remarkably similar course with unsteadiness of gait, coor-
dination problems, and cognitive decline from the age of
10 years. At last clinical examination at ages 31, 18, and
12 years, respectively, all were still able to walk indepen-
dently but showed short and thin stature, a cerebellar
syndrome, marked vertical gaze palsy, hearing loss, and a
dystonic or athetotic movement disorder. Brain MRI
showed mild cerebellar atrophy in all affected siblings
(Figure 2).
Family 3 consists of one affected sister (F3:II.1) and one
healthy brother, born to healthy unrelated parents from
Finland. The affected sister presented at the age of 7 years
with tremor, oculomotor apraxia, and dysarthria. Last
clinical examination at age 18 years showed a cerebellar
syndrome and cognitive impairment. Brain MRI revealed
mild to moderate cerebellar atrophy (Figure 2). Muscle
biopsy was unremarkable regarding morphology, histo-
chemistry, and ultrastructure but respiratory chain enzyme
analysis showed a slight decrease in complex IV activity.er 1, 2016
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Figure 1. Pedigrees of Investigated Families and Structure of SQSTM1
(A) Pedigrees of four families withmutations in SQSTM1. Mutation status of affected (closed symbols) and healthy (open symbols) family
members. n.d., not determined.
(B) Gene structure of SQSTM1with known protein domains and motifs of the gene product and localization of the identifiedmutations.
Intronic regions are not drawn to scale. Abbreviations are as follows: PB1, Phox 1 and Bem1p; ZZ, zinc finger; TRAF6, tumor necrosis
factor receptor-associated factor 6; LIR, LC3-interaction region; KIR, Keap1-interacting; UBA, ubiquitin-associated.Family 4 consists of two affected individuals, one female
(F4:II.1) and one male (F4:II.4), and two healthy siblings,
born to healthy consanguineous parents of Kurdish
descent. Both affected siblings presented at the age of 8
years with a syndrome of ataxia, dysarthria, and vertical
gaze palsy. Last clinical examination at ages 33 and 17
years, respectively, revealed a cerebellar syndrome and
cognitive impairment. Although F4:II.1 is still walking
with a broad-based gait at age 33 years, her brother
(F4:II.4) is wheelchair bound at age 17 years. Brain MRI
and EEG showed normal findings in both. In F4:II:4, mito-
chondrial ATP production rate and respiratory chain
enzyme activities were toward the lower end of normal,
with complex IV activity being mostly affected. In agree-
ment with this, fibroblasts grown on galactose as carbon
source showed a mild complex IV defect (Figure S1).The AmericanWe performed exome sequencing at three centers
(Munich [families 1 and 2], Helsinki [family 3], and Stock-
holm [family 4]) on genomic DNA from three affected
individuals of family 1, individuals F2:II.2 and F3:II.1, as
well as on both affected individuals and their parents of
family 4, essentially as described previously.6
In family 1, individuals F1:II.1 and F1:II.3 have been
investigated in a prior experimentwith a SureSelect Human
All Exon 38 Mb enrichment kit (Illumina). A search for
recessive-type non-synonymous variants with a minor
allele frequency (MAF)< 0.1% in an in-house database con-
taining 7,000 control exomes and the Exome Aggregation
Consortium (ExAC) Server (09/2015) failed to prioritize
likely pathogenic variants common to both individuals.
We speculated that we had missed the responsible variant
due to insufficient coverage of target sequences andJournal of Human Genetics 99, 735–743, September 1, 2016 737
Figure 2. Neuroimaging Findings in SQSTM1/p62 Variant Individuals
(A) BrainMRI (T2-weighted image, axial view) of individual F1:II.6 at the age of 33 years, demonstrating iron accumulation in the globus
pallidus internus.
(B) Brain MRI (T1-weighted image, sagittal view) of individual F2:II.2 at the age of 31 years, demonstrating mild cerebellar atrophy.
(C)BrainMRI (T1-weighted image, sagittal view)of individual F3:II.1at theageof18years showingmild tomoderateupper vermianatrophy.processedDNAof the third affected individual (F1:II.6)with
an updated version of the enrichment kit, SureSelect
Human All Exon 50 Mb V3, potentially providing an
improved coverage of the coding regions. This analysis
identified seven genes carrying potential compound het-
erozygous or homozygous variants, with SQSTM1 being
the only gene carrying two predicted loss-of-function al-
leles (Table S1). Manual inspection of the sequencing data
confirmed that the SQSTM1 (GenBank: NM_003900.4)
variant c.2T>A (p.?) in exon 1 was missed as an alternative
call in the exome datasets of the two other siblings due to
insufficient coverage of this genomic position, which re-
flects a general problem of GC-rich first exons. Subsequent
Sanger sequencing confirmed the c.2T>A variant in a ho-
mozygous state in all affected individuals, with the mother
and healthy siblings being heterozygotes or wild-types.
These results were in line with the observation that the
SQSTM1 locus is locatedwithin one of six regions of interest
of a previously performed SNP-array linkage study per-
formed on this family. Because no paternal samples were
available for carrier testing, we cannot exclude a large dele-
tion on the paternal chromosome. However, analysis of the
gene dosage in individual F1:II.6’s exome dataset using
exome depth as described previously did not indicate any
copy-number variation.7,8
In individual F2:II.2, sequencing was performed using
a SureSelect Human All Exon 38 Mb enrichment kit.
A search for genes carrying putative compound heterozy-
gous or homozygous rare variants identified 30 candidate
genes, 7 of which were affected by variants rated likely
detrimental in silico (see Table S1). Segregation analysis
by Sanger sequencing on DNAs of further family mem-
bers excluded a likely clinical relevance of variants in
five putative candidate genes, leaving a homozygous
frameshift variant c.311_312del (p.Glu104Valfs*48) in
SQSTM1 as the likely candidate. No material was avail-
able to confirm a heterozygous carrier status of the father.738 The American Journal of Human Genetics 99, 735–743, SeptembHowever, we did not detect any evidence of a large het-
erozygous deletion in the exome data of individual
F2:II.2.8
In individual F3:II.1, the exome targets of the affected in-
dividual’s DNA were captured with the Agilent SureSelect
Human All Exon V5 whole exome kit followed by
sequencing with the Illumina HiSeq 2000 platform. The
variant calling pipeline of the Finnish Institute of Molecu-
lar Medicine (FIMM) was used for the reference genome
alignment and variant calling.9 Variants with a Combined
Annotation Dependent Depletion (CADD) C-score less
than 10 were excluded.10 A search for recessive-type non-
synonymous variants with a MAF < 0.1% on the ExAC
Server (09/2015) prioritized three candidate genes: LLGL1
(MIM: 600966), RYR1 (MIM: 180901), and SQSTM1. Vari-
ants in RYR1 have been associated with unrelated auto-
somal-recessive inherited phenotypes (MIM: 255320 and
117000). Variants in LLGL1 have so far not been associated
with human disease and although an effect of the pre-
dictively synonymous variant on splicing cannot be
excluded, we considered it unlikely to be associated
with the disease of individual F3:II.1. A homozygous
SQSTM1 loss-of-function variant with a CADD score
of 45, c.286C>T (p.Arg96*), remained as the top scoring
candidate.
Family 4 was sequenced on the Hiseq 2500 platform (Il-
lumina) using the Agilent SureSelect Human All Exon V4
whole exome kit. The resulting sequences were analyzed
using an in-house Mutation Identification Pipeline (MIP)
as previously described.11 All called variants are scored
and ranked using the Mutation Identification Pipeline
weighted sum model, which uses multiple parameters
but emphasizes Mendelian inheritance patterns, con-
served, rare, and protein-damaging variants. This left a
homozygous c.286C>T (p.Arg96*) SQSTM1 loss-of-func-
tion variant as the top-scoring variant. Sanger sequencing

















































































































Figure 3. Investigation of SQSTM1/p62 Protein and RNA Levels
Western blot studies in SQSTM1/p62 variant fibroblast cell lines indicating that the homozygous variants c.2T>A (p.?) and c.286C>T
(p.Arg96*) result in a loss of SQSTM1/p62 protein. Immunoblotting was done with anti-SQSTM1/p62 antibody (F1:II.6 with Progen
cat# GP62-C; F3:II.1 and F4:II.1,4 with Cell Signaling cat# 5114).
In SQSTM1/p62 variant fibroblasts cell lines of F4:II.1,4, total RNA was isolated for qPCR analysis using Trizol. Reverse transcription for
qRT-PCR analysis was performed using High Capacity cDNA Reverse Transcription Kit (Life Technologies). qRT-PCR was performed on a
QuantStudio 6 (Life Technologies) with Platinum SYBR Green qPCR supermix-UDG (Life Technologies) and gene-specific primers. Error
bars indicate5 SEM; ***p % 0.001; two-tailed unpaired t test. The first two columns refer to controls 1 and 2, and the last two columns
refer to affected individuals F4:II.1 and F4:II.4.SQSTM1 variant co-segregated with the phenotype in line
with autosomal-recessive inheritance.
Biallelic loss-of-function SQSTM1 variants were absent
from 7,000 in-house exomes (Munich) of individuals with
unrelated phenotypes and no such homozygous variants
were observed in ~120,000 alleles of the ExAC Server
(09/2015).Western blot studies in primary fibroblasts avail-
able from individuals F1:II.6, F3.II.1, F4:II.1, and F4:II.4
showed absence of the SQSTM1/p62 protein accompanied
by a severe reduction in SQSTM1 mRNA steady-state levels
in fibroblasts from individuals F4:II.1 and F4:II.4 (Figure 3).
In summary, the identification of three different biallelic
SQSTM1 loss-of-function variants in four unrelated families
with a similar clinical phenotype establishes SQSTM1 as a
gene confidently implicated in this neurodegenerative
disease. The identified variants c.286C>T (p.Arg96*) and
c.311_312del (p.Glu104Valfs*48) affect all three predicted
SQSTM1 isoforms. In contrast, the variant c.2T>A (p.?) af-
fects only the start codon of one out of three predicted
isoforms, and while arguing for the importance of this
isoform in the pathogenesis of the disease, it raises
the possibility of residual mRNA/protein amount. RNA
sequencing in fibroblasts andwhole blood suggested partial
expression of the two other isoforms (Figure S2). However,
the antibody directed against the C terminus of the
SQSTM1/p62 protein common to all three isoforms failed
to provide evidence of any translated SQSTM1 gene prod-
ucts, at least in fibroblasts.The AmericanThemutation c.286C>T has been detected in families F3
and F4. In order to test for the possibility of a shared ances-
tral change, we compared the variation observed in the
~2 Mb region surrounding the variant. Identified rare
(MAF < 1% in public databases) variants were not shared
between subjects of families 3 and 4 carrying the
c.286C>T variant, indicating that this is unlikely a single
ancestral variant but arose independently in the two fam-
ilies, in line with the reportedly Finnish and Kurdish
descent of families 3 and 4, respectively.
The scaffold protein SQSTM1/p62 is highly conserved
among metazoans and was originally identified as a signal
adaptor for the atypical protein kinases C sub-family
(aPKCs).12,13 SQSTM1/p62 serves as a signaling hub in a
variety of key cellular processes such as cell differentiation,
cell growth, osteoclastogenesis, tumorigenesis, amino acid
sensing, and oxidative stress response.14,15 Its interactions
with binding partners are mediated by multiple domains
(Figure 1). SQSTM1/p62 is found in different compart-
ments of the cell including the cytoplasm, nucleus, auto-
phagosomes, and lysosomes. Upon stress induction,
SQSTM1/p62 is activated to enable selective autophagy,
e.g., of cells infected by bacteria, protein aggregates, and
damaged mitochondria.16–20 Earlier studies had suggested
that SQSTM1/p62 is responsible for the PARKIN-mediated
direction of ubiquitinated mitochondria to the auto-
phagosome.17 However, growing evidence indicates that
















































































































   
   
   
   
   
   































































Figure 4. Investigation of Aggregation of Depolarized Mitochondria and Autophagosomal Formation
(A) Naive (no exogenous PARKIN) control and SQSTM1/p62 variant fibroblasts were treated with 20 mM CCCP for 3 and 6 hr and fixed
with 4% PFA. Mitochondria were immunostained with the mitochondrial SSBP and detected with a fluorescent-labeled secondary
antibody (AF568, red), nuclei were stained with DAPI (blue), and images were acquired by confocal microscopy. Depolarization of mito-
chondria using the protonophore CCCP led to the collapse of the mitochondrial network in control and in SQSTM1/p62 variant cells.
(legend continued on next page)
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seems to be indispensable for perinuclear clustering of
depolarized mitochondria in a process of self-oligomeriza-
tion.3,18,19 Furthermore, TBK1-dependent phosphoryla-
tion of SQSTM1/p62 at Ser403 has been shown to promote
the efficacy of autophagosomal engulfment of ubiquiti-
nated mitochondria at an early phase of mitochondrial de-
polarization.21 We therefore studied perinuclear clustering
and clearance of mitochondria in naive as well as GFP-
PARKIN- and YFP-PARKIN-overexpressing control and
SQSTM1/p62 variant fibroblasts after depolarization of
mitochondria with the protonophore carbonyl cyanide
m-chlorophenyl hydrazine (CCCP), the established tool
to study PARKIN-dependent mitophagy in cultured cells.
In naive SQSTM1/p62 variant cell lines, reduced perinu-
clear clustering of mitochondria was detected after 3 hr
CCCP treatment compared to control cells (Figure 4A).
In PARKIN-overexpressing cells (transduced with GFP-
PARKIN or transfected with YFP-PARKIN), depolarization
of mitochondria and subsequent collapse of themitochon-
drial network led to a translocation of PARKIN to the mito-
chondria as indicated by co-localization with mtSSBP
(Figure S3) and TOM20 (Figure 4B), replicating results of
a wide literature in the field.3,18 After 2 hr of CCCP treat-
ment, we found a clear mitochondrial clustering in control
YFP-PARKIN-overexpressing cells but not in SQSTM1/p62
variant cells (Figure 4B). No perinuclear clustering of mito-
chondria was observed after 2 hr treatment of oligomycin
and antimycin (Figure S4). Differences in perinuclear clus-
tering were less obvious between stably overexpressing
GFP-PARKIN control and SQSTM1/p62 variant fibroblasts
after 3 hr of CCCP treatment (Figure S3). We observed no
difference in the overall clearance of mitochondria after
24 hr CCCP treatment in all tested conditions, in line
with SQSTM1/p62 being dispensable for the PARKIN-
dependent disposal of depolarized mitochondria in fibro-
blasts (Figures S3 and S4). In agreement, we observed
no difference in mitochondrial clearance in PARKIN-over-
expressing cells, treated with the respiratory chain inhibi-
tors oligomycin and antimycin after 24 hr (Figure S4) inAfter 3 hr of CCCP treatment, perinuclear clustering of mitochondria
p62 variant fibroblasts (arrows indicate distance from outer cell mem
cell lines were observed after 6 hr of treatment.
(B) Control and SQSTM1/p62 variant fibroblasts were transfected wit
2 hr, followed by 4% PFA fixation. Mitochondria were immunosta
(Santa Cruz cat# sc-11414, RRID: AB_793274) and detected with a fl
acquired by confocal microscopy. Depolarization of mitochondria us
drial network in control and in SQSTM1/p62 variant cells. After 2 h
reduced clustering in SQSTM1/p62-deficient cells. Right panel: quant
chondrial distribution after 2 hr of CCCP treatment. n ¼ 3, 25 cells
previous reports studying the function of p62/SQSTM1 in mitophag
(C) SQSTM1/p62 variant and control cell lines were treated for 24 h
Autophagosomes were immunostained, using antibodies against the
RRID: AB_1279144) and detected with a fluorescent-labeled seconda
microscopy and autophagosomes were counted manually. Right pane
cell. Treatment with CCCP resulted in reduced autophagosome form
(D) SQSTM1/p62 variant and control cell lines were treated for 24 a
CCCP resulted in reduced LC3II levels formation in SQSTM1/p62-defi
levels using ImageJ software.
In (B)–(D), *p % 0.05; **p % 0.01; two-tailed unpaired t test. Error b
The Americanthese cells. We next investigated the autophagic flux in
SQSTM1/p62-deficient and control cell lines by moni-
toring changes in the levels of LC3I/II upon starvation
with and without addition of the lysosomal inhibitors ba-
filomycin or NH4Cl. Concordant with a functional redun-
dancy of involved autophagy adaptors, we observed no
obvious differences between control and SQSTM1/p62
variant cell lines in these assays (Figures S5 and S6). Coloc-
alization of the autophagosomal marker LC3II and
YFP-PARKIN was not affected upon CCCP treatment
(Figure S7). However, depolarization of mitochondria
with CCCP did result in a reduced autophagosome
formation in naive SQSTM1/p62-deficient cells (Figures
4C and 4D), whereas after treatment with oligomycin-
antimycin, no differences were observed between
SQSTM1/p62 variant and control cell lines (Figure S8).
These observations suggest that in dividing cells,
SQSTM1/p62 contributes to the early regulation of mi-
tophagy including perinuclear clustering of mitochondria
and autophagosome formation upon depolarization, but
that it is redundant for mitochondrial removal and auto-
phagic flux.
In mice, the knock out of Sqstm1 leads to mature-
onset obesity, leptine resistance, and impaired glucose
tolerance and insulin resistance potentially mediated
by disturbed regulation of adipocyte differentiation due
to enhanced basal ERK activity.22 Furthermore, the
chronic absence of Sqstm1/p62 promotes mature-onset
neurodegeneration with accumulation of hyperphos-
phorylated tau and neurofibrillary tangles in hippocampal
and cortical neurons manifesting with increased anxiety,
depression, and loss of short-term memory.23 In agree-
ment, individuals deficient of SQSTM1/p62 did present
with severely increased tau and phospho-tau levels in
CSF (see F4:II.1,4 clinical description in the Supplemental
Data).
To our knowledge, biallelic SQSTM1 loss-of-functionmu-
tations have not yet been reported in humans. The present
study establishes absence of SQSTM1/p62 as a molecularcan be observed in control cells, which is less evident in SQSTM1/
brane to clustered mitochondria). No obvious differences between
h YFP-Parkin (Addgene #23955),28 treated with CCCP (20 mM) for
ined using antibodies against the mitochondrial protein TOM20
uorescent-labeled secondary antibody (AF568, red). Images were
ing the protonophore CCCP led to the collapse of the mitochon-
r, mitochondrial clustering can be observed in control cells, with
ification of percent of cells showing a dispersed or aggregatedmito-
per experiment. Morphology classification was done according to
y.
r with the protonophore CCCP (20 mM) and fixed with 4% PFA.
autophagosomal protein LC3II (MBL International cat# M152-3,
ry antibody (AF488, green). Images were acquired by fluorescence
l: quantification of the relative number of autophagosomes in the
ation in SQSTM1-deficient cells. n ¼ 3, 150 cells per experiment.
nd 48 hr with the protonophore CCCP (20 mM). Treatment with
cient cells. Right panel: quantification of the relative LC3II protein
ars indicate 5 SEM from the mean of three replicates.
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defect underlying a childhood- or adolescence-onset
neurodegenerative disorder. The pivotal features of the
affected individuals’ phenotypes were gait abnormalities
(9/9), ataxia mostly of the upper limbs (9/9), dysarthria
(9/9), dystonia (7/9), vertical gaze palsy (7/9), and mild
cognitive decline (7/9). The course was remarkably similar
in all nine affected individuals with onset between age 7 to
15 years and relatively slow progression. BrainMRI showed
cerebellar atrophy in four out of eight individuals and
signal abnormalities in basal ganglia with iron accumula-
tion in two out of eight individuals. Of note, extensive
brain iron deposition in the basal ganglia and substantia
nigra is a characteristic phenotypic feature of a clinically
and genetically heterogeneous group of neurodegenera-
tive disorders subsumed under the umbrella term NBIA
(neurodegeneration with brain iron accumulation).24
Although the exact pathomechanisms leading to
neurodegeneration is unknown in most of the major
NBIA forms, the identification of X chromosome WDR45
(MIM: 300526) mutations in individuals with BPAN
(NBIA 5 [MIM: 300894]) suggested defective autophagy
as a key pathomechanism.25 Screening of a large
cohort of 250 idiopathic NBIA individuals for SQSTM1 var-
iants failed to detect clinically relevant biallelic variants,
indicating that brain iron accumulation is probably an
inconsistent feature in SQSTM1-associated neurodegenera-
tion. Of note, also in the PLA2G6 (MIM: 603604)-associ-
ated NBIA subtype PLAN (MIM: 610217), brain iron accu-
mulation may be absent or subtle early in the disease
course.24
Given the role of SQSTM1/p62 as a key player in a variety
of vital cellular processes, it was unexpected that its
absence is compatible with survival above age 40 years
and that affected individuals display such a circumscribed
neurological phenotype. This observation together with
the findings in mice argues for a redundancy of involved
factors and pathways or effective compensatory mecha-
nisms to maintain cellular homeostasis. Our data indicate
that SQSTM1/p62 functions are of particular importance
in the brain, where the postmitotic nature of neurons
poses especial challenges to the removing of damaged
organelles and misfolded proteins.
In humans, heterozygous missense and truncating
SQSTM1 variants have been associated with the progressive
skeletal disorder Paget disease of the bone (PDB), the neuro-
degenerative disorders ALS and FTD,4 and recently distal
myopathy with rimmed vacuoles.5 Furthermore, 5q copy
number gains comprising SQSTM1 have been associated
with kidney cancer.26 Although several disease alleles are
common to both PDB and ALS/FTD, others have been pro-
posed to be ALS/FTD specific.4 Surprisingly, heterozygous
carriers of SQSTM1 variants in our families showed no
skeletal defects or neurological disease. In keeping with
this, a recent large exome-sequencing study of 2,869 ALS-
affected case subjects and 6,405 control subjects, which
confidently implicated TBK1 (MIM: 604834) and OPTN
(MIM: 602432) in ALS, failed to establish a significant742 The American Journal of Human Genetics 99, 735–743, Septembenrichment of rare SQSTM1 variants relative to control
subjects.27 Therefore, despite SQSTM1 being a promising
ALS candidate gene from a cell biological perspective, addi-
tional statistical andmechanistic evidence is needed for the
implication of hypomorphic alleles, putatively dominant-
acting variants, or SQSTM1 haploinsufficiency in neurode-
generation. Thepuzzlingvarietyof diseases and inheritance
patterns associated with SQSTM1 variants suggests
complex genotype/phenotype relationships and points
to the possibility of currently unidentified modifying
genes and gene-environment interactions.Supplemental Data
Supplemental Data include clinical descriptions, seven figures,
and one table and can be found with this article online at
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